Publications by authors named "Gail D Wygant"

Claim this Profile
B
Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.
Derek Weycker, Gail DeVecchis Wygant, Jennifer D Guo, Theodore Lee, Xuemei Luo

Blood Adv· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review of societal costs associated with stroke, bleeding and monitoring in atrial fibrillation.
Amber L Martin, Alessandra G Reeves, Samantha E Berger, Manuela Di Fusco, Gail D Wygant

J Comp Eff Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Derek Weycker, Xiaoyan Li, Gail DeVecchis Wygant, Theodore Lee, Melissa Hamilton

Thromb Haemost· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Derek Weycker, Xiaoyan Li, Gail DeVecchis Wygant, Theodore Lee, Melissa Hamilton

Thromb Haemost· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China.
Wen Chen, Thomas Ward, Mai Ping Tan, Jing Yan, Peter Feng Wang, Gail D Wygant

J Comp Eff Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis